CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate
  • AACR 2015: Report from Day 3

    Results of two high-profile clinical trials, among others, are covered on the meeting's third day.

    April 20, 2015| Matthew Tontonoz
  • AACR 2015: Report from Day 2

    Our report on the latest developments in cancer immunotherapy from day 2 at the annual AACR meeting…

    April 19, 2015| Matthew Tontonoz
  • AACR 2015: Report from Day 1

    Presentations from the annual meeting of the American Association for Cancer Research span many cancer immunotherapy topics.

    April 19, 2015| Matthew Tontonoz
  • Special Issue of Science Devoted to Cancer Immunotherapy

    CRI scientists review the state of cancer immunotherapy in the latest issue of Science magazine.

    April 6, 2015| Matthew Tontonoz
  • What Ever Happened to Coley’s Toxins?

    Experts today agree that a 100-year-old therapy cured cancer in some cases. Why did it fall out…

    April 2, 2015| Matthew Tontonoz
  • Beyond Magic Bullets: Helen Coley Nauts and the Battle for Immunotherapy

    How one woman who lacked a college degree took on the cancer establishment and changed the course…

    April 1, 2015| Matthew Tontonoz
  • Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma

    Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.

    March 24, 2015| Matthew Tontonoz
  • CRI’s James Allison, Arming the Immune System

    The director of CRI's Scientific Advisory Council talks immunotherapy with the New York Times.

    March 9, 2015| Matthew Tontonoz
  • Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer

    The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…

    March 4, 2015| Matthew Tontonoz

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute